Morgan Stanley Ab Cellera Biologics Inc. Transaction History
Morgan Stanley
- $1.39 Trillion
- Q4 2024
A detailed history of Morgan Stanley transactions in Ab Cellera Biologics Inc. stock. As of the latest transaction made, Morgan Stanley holds 937,385 shares of ABCL stock, worth $2.36 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
937,385
Previous 589,653
58.97%
Holding current value
$2.36 Million
Previous $1.53 Million
79.83%
% of portfolio
0.0%
Previous 0.0%
Shares
20 transactions
Others Institutions Holding ABCL
# of Institutions
165Shares Held
120MCall Options Held
233KPut Options Held
339K-
Baker Bros. Advisors LP New York, NY27.5MShares$69.4 Million0.89% of portfolio
-
Baillie Gifford & CO12.2MShares$30.8 Million0.03% of portfolio
-
Voya Investment Management LLC Atlanta, GA10.6MShares$26.8 Million0.04% of portfolio
-
Capital World Investors Los Angeles, CA7.93MShares$20 Million0.0% of portfolio
-
Prosight Management, LP Dallas, TX7.35MShares$18.5 Million6.4% of portfolio
About AbCellera Biologics Inc.
- Ticker ABCL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 285,139,008
- Market Cap $719M
- Description
- AbCellera Biologics Inc. develops antibody discovery platform. Its full-stack, artificial intelligence-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that could be developed as drugs. As of December 31, 2021, the company had 156 discovery programs that are either completed, in ...